Reaction: Azilsartan medoxomil to 1 product

Reaction
Azilsartan medoxomil
DB08822
    Azilsartan
    DBMET03335
    Reaction type
    hydrolysis
    Direction
    Major circulating metabolite?
    Yes
    Spontaneous?
    Yes
    Activity
    active
    References
    1. Jones JD, Jackson SH, Agboton C, Martin TS: Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker. P T. 2011 Oct;36(10):634-40. [Article]
    2. Kuze Y, Kogame A, Jinno F, Kondo T, Asahi S: Development, validation and application of the liquid chromatography tandem mass spectrometry method for simultaneous quantification of azilsartan medoxomil (TAK-491), azilsartan (TAK-536), and its 2 metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Sep 15;1001:174-81. doi: 10.1016/j.jchromb.2015.07.047. Epub 2015 Jul 30. [Article]
    3. De Caterina AR, Harper AR, Cuculi F: Critical evaluation of the efficacy and tolerability of azilsartan. Vasc Health Risk Manag. 2012;8:299-305. doi: 10.2147/VHRM.S22589. Epub 2012 May 14. [Article]
    4. FDA Approved Drug Products: Edarbi (azilsartan medoxomil) oral tablets [Link]
    Comments
    Not Available
    Enzymes
    Not Available